Janet Lee, MD
Pulmonary Disease · Saint Louis, MONPI 1912979824
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $142,484 of the $143,429 with a category attached, or 99.3%. Janssen Research & Development, LLC accounts for 99.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $79,638 and has fallen 98.9% since, to $889 in 2025. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $3984.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$142K
- Abbott$889
- Rigel Pharmaceuticals, Inc.$43
- AstraZeneca$12
What the payments were for
- Consulting fees$142,48499%
- Travel & lodging$8891%
- Food & beverage$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 31 | $142,484 |
| Abbott | 3 | $889 |
| Rigel Pharmaceuticals, Inc. | 1 | $43 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DRAGONFLY OPSTAR$880
How this compares
$143,429 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Edward CharbekSaint Louis$372K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
- Shiraz DaudSaint Louis$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.